Annual Surveillance Summary: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections in the Military Health System (MHS), 2016
Abstract
The EpiData Center Department (EDC) conducts routine surveillance of methicillin-resistant Staphylococcus aureus (MRSA) incidence and prevalence among all beneficiaries seeking care within the Military Health System (MHS). This report describes demographics, clinical characteristics, prescription practices, and antibiotic resistance patterns observed for MRSA in calendar year (CY) 2016. Multiple data sources were linked to assess descriptive and clinical factors related to MRSA. Health Level 7 (HL7)-formatted Composite Health Care System (CHCS) microbiology data identified S. aureus infections resistant to oxacillin, cefoxitin, or methicillin. These infections were matched to HL7-formatted CHCS pharmacy data to assess prescription practices, the Standard Inpatient Data Record (SIDR) to determine healthcare-associated exposures, Defense Manpower Data Center (DMDC) rosters to determine burden among Department of Defense (DOD) active duty (AD) service members, and the DMDC Contingency Tracking System (CTS) to determine Department of the Navy (DON) deployment-related infections. Overall, incidence rates of MRSA in the general United States (US), MHS beneficiary, and DOD AD populations are decreasing. Inducible clindamycin resistance is slowly increasing in the MHS; no additional changes in antibiotic susceptibility emerged in 2016. Clindamycin, trimethoprim/sulfamethoxazole, doxycycline, and vancomycin remain viable treatments for MRSA, although clindamycin should be used cautiously in the inpatient setting due to reduced efficacy. Current infection control practices appear effective and continued surveillance is recommended.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2017
- Accession Number
- AD1040547
Entities
People
- Jessica Spencer
- Uzo Chukwuma
Organizations
- Navy and Marine Corps Public Health Center